Generated by AI
Valion Bio, Inc. Common Stock is the equity security of Valion Bio, Inc., a late-stage biopharmaceutical company focused on developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its current pipeline centers on Entolimod, a TLR5 agonist being developed for acute radiation syndrome and other conditions associated with immune suppression, alongside Entolasta, a next-generation variant intended for chronic applications. The company also provides contract development and manufacturing organization services, adding a non-clinical business segment that supports its broader life sciences activities. Valion Bio’s work is aimed at medical needs in areas such as radiation injury, neutropenia, and oncology supportive care, positioning the company within the biotechnology and specialized therapeutics market. Headquartered in San Antonio, Texas, Valion Bio combines drug development with service capabilities, making its common stock tied to a diversified healthcare-focused business model.
Website47685 Lakeview Blvd.
Fremont, CA, 94538
United States
Summary of May 5's posts. Generated by AI.
Summary of Apr 28's posts. Generated by AI.
Summary of Dec 23's posts. Generated by AI.
Investors talking about TIVC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.